Infinimmune announced a $75 million Series A to advance two antibody programs into the clinic for atopic dermatitis. The round was co-led by Regeneron Ventures and Playground Global, with Regeneron also backing the biotech, and Merck participating as a partner. The company’s lead assets include IFX-101, targeting IL-22, and IFX-201, targeting IL-13—both designed to compete in a crowded atopic dermatitis biologics market by emphasizing potentially improved durability and mechanism coverage. For deal-making and BD teams, the financing underscores continued investment in next-generation biologics that aim to improve on Dupixent-like cytokine targeting, particularly when differentiation claims center on durability and switching efficacy.